KRS Capital Management’s BioNTech BNTX Stock Holding History

KRS Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$25K	–	149
2021 Q4	$25K	Buy	+100	New	+$27.4K	0.02%	274

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KRS Capital Management's BNTX Position: Q1 2022 in Review

KRS Capital Management sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 100 shares — an estimated $25K sold.

KRS Capital Management first reported a position in BNTX in Q4 2021 and held it in 1 quarter. The position peaked at $25K in Q4 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

KRS Capital Management reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
KRS Capital Management sold 100 BioNTech shares in Q1 2022, an estimated $25K.
KRS Capital Management first reported a position in BioNTech in Q4 2021 and held it in 1 quarter.
KRS Capital Management's BioNTech position peaked at $25K in Q4 2021.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.